Floatz logo

Ulixertinib

KRAS Activating Mutation

Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the KRAS Activating Mutation cohort.

Asset / SponsorPhaseRating
Avutometinib
Verastem, Inc.
Phase 2BB
Defactinib
Verastem, Inc.
Phase 2BB
Carboplatin
Shirish M Gadgeel
Phase 2CCC
Durvalumab
Shirish M Gadgeel
Phase 2CCC
Adagrasib
Verastem, Inc.
Phase 1/2CCC
Sotorasib
Verastem, Inc.
Phase 1/2CCC

Same molecule, other indications

Ulixertinib is also rated in:

neoplasmDormant
B
Indicative ·
57 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
rectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →